You have 9 free searches left this month | for more free features.

Epratuzumab

Showing 1 - 25 of 42

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Waldenstrom Macroglobulinemia Trial in New York (Epratuzumab (hLL2- anti-CD22 humanized antibody))

Terminated
  • Waldenstrom Macroglobulinemia
  • Epratuzumab (hLL2- anti-CD22 humanized antibody)
  • New York, New York
  • +1 more
Aug 12, 2021

Non Hodgkin's Lymphoma, NHL, Aggressive NHL Trial in United States (Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab

Withdrawn
  • Non Hodgkin's Lymphoma
  • +3 more
  • Veltuzumab and 90Y-Epratuzumab Tetraxetan
  • +2 more
  • Newark, Delaware
  • +6 more
Aug 12, 2021

Non-Hodgkin's Lymphoma, Lymphoma, B-Cell Trial (radiolabeled epratuzumab)

Completed
  • Non-Hodgkin's Lymphoma
  • Lymphoma, B-Cell
  • radiolabeled epratuzumab
  • (no location specified)
Aug 12, 2021

Non-Hodgkins Lymphoma Trial in Philadelphia, Houston (hLL2 (epratuzumab))

Terminated
  • Non-Hodgkins Lymphoma
  • hLL2 (epratuzumab)
  • Philadelphia, Pennsylvania
  • +1 more
Aug 12, 2021

Lymphoma Trial in Worldwide (immunoscintigraphy, technetium Tc 99m epratuzumab)

Unknown status
  • Lymphoma
  • immunoscintigraphy
  • technetium Tc 99m epratuzumab
  • Los Angeles, California
  • +7 more
Aug 12, 2021

Lymphoma Trial in Worldwide (immunoscintigraphy, technetium Tc 99m epratuzumab)

Unknown status
  • Lymphoma
  • immunoscintigraphy
  • technetium Tc 99m epratuzumab
  • Los Angeles, California
  • +7 more
Aug 12, 2021

Systemic Lupus Erythematosus Trial in Worldwide (Placebo, Epratuzumab)

Completed
  • Systemic Lupus Erythematosus
  • Placebo
  • Epratuzumab
  • Birmingham, Alabama
  • +132 more
Nov 20, 2020

Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive Trial in Monrovia,

Recruiting
  • Blasts 5 Percent or More of Bone Marrow Nucleated Cells
  • +4 more
  • ADCT-602
  • Monrovia, California
  • +1 more
Dec 7, 2022

NHL, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell Trial in United States (veltuzumab)

Completed
  • NHL
  • +17 more
  • veltuzumab
  • Savannah, Georgia
  • +4 more
Aug 12, 2021

Lymphoma Trial in United States (epratuzumab, rituximab, cyclophosphamide)

Completed
  • Lymphoma
  • epratuzumab
  • +5 more
  • Scottsdale, Arizona
  • +161 more
Oct 1, 2019

Follicular Lymphoma Trial in New York (90Y-epratuzumab tetraxetan, veltuzumab)

Terminated
  • Follicular Lymphoma
  • 90Y-epratuzumab tetraxetan
  • veltuzumab
  • New York, New York
    Weill Cornell Medical College
Jan 26, 2018

Systemic Lupus Erythematosus Trial in Worldwide (Epratuzumab, Placebo)

Completed
  • Systemic Lupus Erythematosus
  • Epratuzumab
  • Placebo
  • Birmingham, Alabama
  • +140 more
Aug 31, 2018

B ALL, CD22+ Expression, Refractory B-ALL Trial in France (Epratuzumab)

Completed
  • B ALL
  • +2 more
  • Epratuzumab
  • Angers, France
  • +10 more
Feb 26, 2018

Systemic Lupus Erythematosus Trial in Worldwide (Epratuzumab)

Completed
  • Systemic Lupus Erythematosus
  • Epratuzumab
  • Birmingham, Alabama
  • +227 more
Sep 3, 2018

Recurrent Childhood Acute Lymphoblastic Leukemia Trial in Worldwide (L-asparaginase, doxorubicin HCl, therapeutic

Completed
  • Recurrent Childhood Acute Lymphoblastic Leukemia
  • Birmingham, Alabama
  • +45 more
Nov 14, 2017

CD22+ Relapsed/Refractory B-ALL Trial in Clermont-Ferrand (90Y-epratuzumab tetraxetan, chemo/ immunotherapy)

Withdrawn
  • CD22+ Relapsed/Refractory B-ALL
  • 90Y-epratuzumab tetraxetan
  • chemotherapy/ immunotherapy
  • Clermont-Ferrand, France
    CHU de Clermont-Ferrand
Jan 17, 2017

Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia Trial (90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG, Busulfan, allogeneic

Withdrawn
  • Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
  • 90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG
  • +4 more
  • (no location specified)
Jan 17, 2017

Leukemia Trial in United States (biological, drug, other)

Completed
  • Leukemia
  • epratuzumab
  • +3 more
  • Little Rock, Arkansas
  • +80 more
Oct 3, 2017

Systemic Lupus Erythematosus Trial in Fukuoka, Kitakyusyu, Tokyo (Epratuzumab)

Completed
  • Systemic Lupus Erythematosus
  • Epratuzumab
  • Fukuoka, Japan
  • +5 more
Apr 11, 2016

Lymphoma Trial in United States (epratuzumab, rituximab)

Completed
  • Lymphoma
  • epratuzumab
  • rituximab
  • San Diego, California
  • +42 more
Jul 1, 2016

Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia Trial in New York (hLL1)

Completed
  • Non-Hodgkin's Lymphoma
  • Chronic Lymphocytic Leukemia
  • New York, New York
    Weill Cornell Medical College
May 25, 2018

Systemic Lupus Erythematosus Trial in London (Epratuzumab sc, Epratuzumab iv)

Completed
  • Systemic Lupus Erythematosus
  • Epratuzumab sc
  • Epratuzumab iv
  • London, United Kingdom
    01
May 11, 2015

Acute Lymphoblastic Leukemia Trial in Nantes (Epratuzumab and 90Y-Epratuzumab)

Unknown status
  • Acute Lymphoblastic Leukemia
  • Epratuzumab and 90Y-Epratuzumab
  • Nantes, France
    CHU Nantes
Jun 24, 2014

Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia Trial in United Kingdom (humanised mAb, veltuzumab, humanised mAb

Unknown status
  • Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia
  • humanised monoclonal antibody, veltuzumab
  • +2 more
  • Birmingham, United Kingdom
  • +9 more
Jul 11, 2014